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Gregory L. Moneta, MD, Section EditorEndoscopic Lumbar Sympathectomy for Plantar Hyperhidrosis
Rieger R, Pedevilla S, Pöchlauer S. Brit J Surg 2009;96:1422-8.
Conclusion: In patients with severe plantar hyperhidrosis, endovascu-
lar lumbar sympathectomy is safe and effective.
Summary: Primary plantar hyperhidrosis is characterized by excessive
secretion by eccrine sweat glands of the feet. The etiology is unknown and
symptoms include cold cyanotic skin, skin maceration, bacterial and fungal
infection, and bromidrosis (foul-smelling feet). Interrupting innervation of
the sweat glands stops sweat secretion and has been used since the 1920’s to
treat hyperhidrosis. Whereas lumbar sympathectomy has been used to treat
plantar hyperhidrosis, use of this operation for this condition is relatively
infrequent. The authors’ present data regarding potential benefit of lumbar
sympathectomy in patients with plantar hyperhidrosis treated with an endo-
scopic approach. Ninety patients had 178 endoscopic resections of lower
sympathetic lumbar trunks for an indication of severe plantar hyperhidrosis.
There were 59 men and 31 women. Mean follow up was 24 (range, 3-45)
months. There were no perioperative deaths. Only three patients had post
operative complications.
The procedure is performed under general anesthesia with the patient
in a hyper-extended flank position. Projection of lumbar vertebral bodies on
the anterior abdominal wall was marked fluoroscopically. Retroperitoneos-
copy was performed using three trocars with continuous carbon dioxide
insufflations. The lumbar sympathetic trunk is exposed at the level of third
and fourth lumbar vertebral bodies. Metal clips are placed above and below
transaction sites and the sympathetic trunk resected between the clips, along
with ganglia for L3 and/or L4. Evidence of postoperative sympathetic
deintervention of the feet was present in all patients. In 97% (n  87),
hyperhidrosis was eliminated. It recurred in 3%. Postsympathetic neuralgia
occurred in 42% and compensatory sweating in 42%. One patient had
temporary loss of ejaculation. Ninety-six percent said they were very or partly
satisfied and 92% would have the procedure repeated if required.
Comment: Conservative treatment of hyperhidrosis can improve
symptoms. However, it is usually ineffective in severe cases and certainly does
not affect long term outcome of the disease. Complications of postsympa-
thetic neuralgia and compensatory sweating were both frequent in this
series. Postsympathetic neuralgia however was minor and temporary and
only one patient had severe compensatory sweating. Permanent sexual
dysfunction appears unlikely as long as sympathectomy is below the level of
third or fourth lumbar vertebral body. The technique appears to be reason-
able treatment for patients with severe plantar hyperhidrosis.
Endovascular versus Open Repair of Abdominal Aortic Aneurysm
The United Kingdom EVAR Trial Investigators. New Engl J Med 2010;
362:1863-71.
Conclusion: Endovascular repair of abdominal aortic aneurysm (AAA)
has lower operative mortality than open repair. There is no difference in
aneurysm-related or total mortality in the long term. There are increased
rates of graft complications with endovascular repair, more reinterventions,
and endovascular repair is more costly.
Summary: Lower 30-day operative mortality with endovascular versus
open surgical repair of AAA has been demonstrated in three large random-
ized trials (Lancet 364:843-8, N Engl J Med 2004;351:1607-18, and JAMA
2009;309:1535-42). Open abdominal aneurysm repair appears durable
(JVS 1997;25:277-84 and JVS 2007;46:669-75). However, little long-term
follow-up of endovascular repair is available. The EUROSTAR registry
provides registry data for a mean follow-up of only three years and
incorporates many endografts no longer in current use (Arch Surg
2007;142:33-41).
This report from the United Kingdom EVAR investigators presents
long-term follow-up data of the EVAR 1 trial. In EVAR 1, from 1999
through 2004, there were 1252 patients with AAAs 5.5 cm who were
randomly allocated to undergo either endovascular or open repair at 37
hospitals in the United Kingdom. There were 626 patients in each group.
Resource use, graft-related complication, reinterventions, and rates of death
were then determined until the end of 2009. In the endovascular repair
group and open repair group, 30-day operative mortalities were 1.8% and
4.3%, respectively (adjusted odds ratio for endovascular repair compared to
open- epair, 0.39; 95% CI, 0.18 to 0.87; P  .02). Early benefit of
endovascular repair with respect to aneurysm-related mortality was lost by
the end of the study, at least partially, because of fatal endograft ruptures
(adjusted hazard ratio, 0.92; 95% CI, 0.57 to 1.49; P .73). No significant
difference between the two groups in the rate of death from any cause was
present by the end of follow-up (adjusted hazard ratio, 1.03; 95% CI, 0.86
252to 1.23; P .72). There were higher rates of graft-related complications and
reinterventions with endovascular repair. New complications occurred up to
8 years following randomization, contributing to overall higher cost of
endovascular repair.
Comment: The value of the study is the long-term prospective nature
of the data and excellent follow-up with very few patients lost to follow-up.
The results of the study, in general, are not surprising in that they confirm
previously published midterm findings of the EVAR 1 trial and other trials
evaluating endovascular vs open repair of AAAs. Operative mortality with
endovascular AAA repair is significantly lower than with open AAA repair
and aneurysm-related mortality is reduced early on. Early benefit, however,
is “completely lost in the longer-term” with no differences in long-term
mortality and higher aneurysm-related mortality after 4 years in the
patients treated with EVAR. The authors note secondary rupture after AAA
repair was associated only with EVAR and “appeared” to explain the late
aneurysm-related mortality in the EVAR patients. These data indicate EVAR
for AAA is not as big a win for patients in the long-term as was hoped and,
with the current cost structure, is clearly a loss for the economics of health
care system.
Endovascular Repair of Aortic Aneurysm in Patients Physically Ineli-
gible for Open Repair
The United Kingdom EVAR Trial Investigators. New Engl J Med 2010;
362:1872-80.
Conclusion: In patients ineligible for open repair, endovascular repair
of abdominal aortic aneurysm (AAA) is associated with a lower rate of
aneurysm-related mortality than no repair. Endovascular repair, however, is
not associated with a reduction in the rate of death from any cause. Rate of
graft-related complications and reinterventions were high and contributed
to increased cost.
Summary: An early premise of endovascular repair of AAA was that it
would be used in patients ineligible for open surgical repair with the
expectation that life would be prolonged by eliminating the risk of fatal
aneurysm rupture. Midterm results of EVAR 2 showed no benefit of
endovascular repair on total or aneurysm-related mortality up to 4 years of
follow-up (Lancet 2005;365:2187-92). In EVAR 2, operative mortality was
higher than anticipated (9%) and there was a 68% mortality at 4 years. In
addition, belated rupture of large, untreated aneurysms was lower than
anticipated (9 ruptures per 100 person-years). The current study was de-
signed to test the hypothesis that the benefits of endovascular repair may take
longer than four years to become apparent.
In EVAR 2, 404 patients with AAAs 5.5 cm in diameter and consid-
ered ineligible for open repair were randomized to either undergo endovas-
cular repair or no repair. The study was conducted in 33 hospitals in the
United Kingdom from 1999 through 2004. The endovascular repair group
consisted of 197 patients, and 207 were assigned to no intervention. Until
the end of 2009, patients were followed for graft related complications,
reinterventions, and rates of death.
The endovascular repair group 30-day operative mortality was 7.3%.
Overall rate of AAA rupture in the no intervention group was 12.4 per 100
person-years (95% CI, 9.6 to 16.2). There was lower AAA-related mortality
in the endovascular repair group (adjusted hazard ratio, 0.53; 95% CI, 0.32
to 0.89; P  .02). However, the advantage of decreased AAA-related
mortality did not result in any benefit of total mortality (adjusted hazard
ratio, 0.99; 95% CI, 0.78 to 1.27; P  .97). Of patients surviving endovas-
cular repair, 48% had graft-related complications. Within the first 6 years,
27% required reintervention. Over the 8 years of follow up, endovascular
repair was considerably more expensive than no repair (cost difference, U.S.
$ 14,867; 95% CI, 11,556 to 18, 176).
Comment: The midterm results of the EVAR 2 reported in 2005 did
not support endovascular repair of AAAs in patients considered unfit for
open repair. Now, with longer follow-up, the authors report benefit of
endovascular repair in terms of aneurysm-related mortality but not in long
term all-cause mortality. Patients in the study had a limited life expectancy,
regardless of whether the aneurysm was managed with EVAR or no inter-
vention was performed. There were few survivors beyond 8 years in either
group. Many patients in the no intervention group crossed over to EVAR
and these patients were, on post hoc analysis, found to be more “fit” than
those that did not cross over. There were only two late ruptures in the EVAR
group; perhaps related to the limited survival of the patients in general. One
conclusion is the patients did not survive long enough to die of rupture
following EVAR. Looking at both the late results of EVAR 1 and EVAR 2,
one might conclude poor risk patients can, in terms of aneurysm related
